These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24318486)

  • 21. Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants among treatment Naïve patients, 5 years after active introduction of HAART in Kuala Lumpur, Malaysia.
    Ong LY; Razak SN; Lee YM; Sri La Sri Ponnampalavanar S; Syed Omar SF; Azwa RI; Tee KK; Kamarulzaman A
    J Med Virol; 2014 Jan; 86(1):38-44. PubMed ID: 24127302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic.
    Charpentier C; Gody JC; Mbitikon O; Moussa S; Matta M; Péré H; Fournier J; Longo Jde D; Bélec L
    AIDS Res Hum Retroviruses; 2012 Jan; 28(1):87-94. PubMed ID: 21599597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
    Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
    J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
    Charpentier C; Gody JC; Tisserand P; Matta M; Péré H; Fournier J; Mbitikon O; Bélec L
    Antivir Ther; 2011; 16(8):1347-50. PubMed ID: 22155917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological Suppression and Patterns of Resistance Amongst Patients on Antiretroviral Therapy at 4 Nigerian Military Hospitals.
    Babajide K; Ayemoba O; Terfa K; Ake J; Crowell TA; Adamu Y; Mohammed T; Okoye I; Odeyemi S; Crawford K; Hughes L; Akintunde E; Umar T; Hamm TE; Njoku OS
    Curr HIV Res; 2017; 15(2):146-151. PubMed ID: 28521719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
    Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil.
    Ferreira AS; Cardoso LP; Stefani MM
    J Med Virol; 2011 Aug; 83(8):1301-7. PubMed ID: 21678433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
    Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission of HIV-1 drug resistance in Benin could jeopardise future treatment options.
    Chamberland A; Diabaté S; Sylla M; Anagounou S; Geraldo N; Zannou DM; Labbé AC; Worobey M; Alary M; Tremblay C
    Sex Transm Infect; 2012 Apr; 88(3):179-83. PubMed ID: 22158948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV reverse-transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in envelope sequences.
    Lipscomb JT; Switzer WM; Li JF; Masciotra S; Owen SM; Johnson JA
    J Infect Dis; 2014 Dec; 210(11):1827-37. PubMed ID: 24924164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.